secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZyVersa Therapeutics, Inc. (ZVSA)
CIK:        0001859007
Form:       8-K/A
Filed at:   2023-01-27T23:59:59+00:00
Accession:  0001493152-23-002764
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ZyVersa amends pro forma to reflect reverse merger; adds ~$105M IPR&D asset
---------------------------------------------------------------------------

- Pro forma updated to forward merger (ZyVersa as VIE); ~$105M IPR&D/goodwill recorded on balance sheet.
- Combined pro forma net loss: $20.96M for 9mo Sep 2022, $8.91M for FY2021.
- Actual redemptions of 7.67M shares for $78.0M; 6.72M shares issued to ZyVersa equity holders.
- Transaction costs $5.2M settled via $1.7M Series B preferred and $3.5M cash; deferred underwriting $3.4M settled in Series B.
- Pro forma total assets $113.4M as of Sep 30, 2022, primarily from IPR&D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859007/000149315223002764/0001493152-23-002764-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859007/000149315223002764/form8-ka.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-002764

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer